EULAR recommendations for the management of systemic lupus erythematosus: 2023 updateAntonis Fanouriakis, Dimitrios T. Boumpas, Thomas Dörner et al.|Annals of the Rheumatic Diseases|2023Cited by 913
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trialRichard Furie, Raj Tummala, Eric F. Morand et al.|The Lancet Rheumatology|2019Cited by 478
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)Eric F. Morand, Thomas Dörner, Edward M Vital et al.|The Lancet|2023Cited by 151
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trialsEdward M Vital, Raj Tummala, Eric F. Morand et al.|Annals of the Rheumatic Diseases|2022Cited by 141
Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to considerAgata Burska, Edward M Vital|RMD Open|2023Cited by 24